comparemela.com

Latest Breaking News On - David borah - Page 1 : comparemela.com

Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

05.06.2024 - WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) - Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for .

Diamond hillKaplan krochukBarrow hanley mewhinney straussDavid borahGreenbrier partners capital managementAdirondack researchFirst wilshire securities management incWestwood holdings group incInvestment groupConstitution research management incPunch associatesPart advisorsAllianz global investorsAristotle capital bostonAscend wealth advisorsBarrow hanley mewhinney

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesCaroline loewDavid borahKatie sullivanExchange commissionAmerican society of clinical oncologyDrug administrationAmerican association of clinical researchCorporate highlightsAmerican societyClinical oncologyAmerican associationClinical researchQuarter ended marchMural oncologyPrivate securities litigation reform act

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

David borahKatie sullivanStock optionIncentive planNasdaq listing ruleMural oncology

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass and DUBLIN, May 03, 2024 Mural Oncology plc , a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop.

Katie sullivanDavid borahStock optionIncentive planNasdaq listing ruleMural oncology

Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 Mural Oncology plc , a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to.

United statesSarina piha paulDavid borahKatie sullivanAmerican society of clinical oncologyAmerican societyClinical oncologyDevelopmental therapeuticsMural oncology

vimarsana © 2020. All Rights Reserved.